SCHEMBL7424355

SCHEMBL7424355

CC1(C)CCc2cc(O)c(O)cc2C1=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.36
EGFR P00533 1/20 0.36
MAPT P10636 5/20 0.35
RECQL P46063 5/20 0.35
TDP1 Q9NUW8 5/20 0.35
HSD17B10 Q99714 4/20 0.35
KDM4E B2RXH2 4/20 0.35
HPGD P15428 4/20 0.35
ALDH1A1 P00352 3/20 0.35
CYP3A4 P08684 2/20 0.35
THRB P10828 2/20 0.35
ALOX12 P18054 2/20 0.35
CASP1 P29466 2/20 0.35
BLM P54132 2/20 0.35
CASP7 P55210 2/20 0.35
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
MAPK1 P28482 2/20 0.33
GRM5 P41594 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3050076 0.79 MAOA (0.50) SMN1; SMN2KDM4EALDH1A1ESR1ESR2
SCHEMBL9588126 0.78 KDM1A (0.35) SMN1; SMN2MAPK1GRM5
SCHEMBL7514048 0.75 MEN1 (0.49) ACHESMN1; SMN2MAPTKDM4EHPGD
SCHEMBL22477463 0.72 ALDH1A1 (0.46) MAPTRECQLTDP1HSD17B10KDM4E
SCHEMBL8678472 0.72 ALDH1A1 (0.46) MAPTRECQLTDP1HSD17B10KDM4E
SCHEMBL447986 0.71 TDP1 (0.51) TDP1MEN1KMT2AUSP2
SCHEMBL27463810 0.71 CA9 (0.41) SMN1; SMN2MAPTTDP1HSD17B10KDM4E
SCHEMBL9588334 0.71 PARP10 (0.47) SMN1; SMN2TDP1GRM5
SCHEMBL9587877 0.71 HTR2A (0.46) SMN1; SMN2
SCHEMBL9589413 0.71 SRD5A1 (0.45) ACHESMN1; SMN2GRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020037931-A1 Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them PORTELA & C.A., S.A. (PT) 2002-03-28 US disclosed
EP-1167341-A1 Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them Portela & Ca., S.A. (PT) 2002-01-02 EP disclosed
WO-2001098250-A1 SUBSTITUTED NITRATED CATECHOLS, THEIR USE IN THE TREATMENT OF SOME CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM PORTELA & CA SA (PT) 2001-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020037931-A1 Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them SLC6A2, COMT, SLC6A3 ACHE 16/4885SMN1; SMN2 281/4885EGFR 3885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.